CYBB and breast cancer: Specifically, data mined from Radich and colleagues noted that, while the majority of genes from chronic phase patients with relapse after imatinib treatment looked similar to that of advanced phase (BC) patients [41], other genes, such as the NOX2-related genes shown here, were uniquely altered in patients with TKI-resistance, suggesting potential roles for these molecules in the resistance phenotype.